Clinical marker of platelet hyperreactivity in diabetes mellitus

Diabetes and Metabolism Journal

Volumn 37, Issue 6, 2013, Pages 423-428

  Kim, Jin Hwa ^a   Bae, Hak Yeon ^a   Kim, Sang Yong ^a  

^a Chosun University   (South Korea)

Author keywords

Blood platelets; Diabetes mellitus; Hyperreactivity; Marker

Indexed keywords

BIOLOGICAL MARKER; CD40 LIGAND; CELL ADHESION MOLECULE; PLATELET SURFACE RECEPTOR; REACTIVE OXYGEN METABOLITE; THROMBOCYTE RECEPTOR; THROMBOXANE A2; UNCLASSIFIED DRUG;

CELL ACTIVITY; DIABETES MELLITUS; DISEASE ASSOCIATION; HUMAN; NONHUMAN; PATHOGENESIS; PLATELET HYPERACTIVITY; PLATELET MICROPARTICLE; PREDICTION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; RISK FACTOR; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE DISORDER; THROMBOCYTE VOLUME; THROMBOSIS;

EID: 84892169677     PISSN: 22336079     EISSN: 22336087     Source Type: Journal    
DOI: 10.4093/dmj.2013.37.6.423     Document Type: Review

References (51)

1. Nathan DM. Long-term complications of diabetes mellitus. N Engl J Med 1993;328:1676-85.
2. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-44.
3. Kang HM, Lee YJ, Kim DJ. The association of self-reported coronary heart disease with diabetes duration in Korea. Diabetes Metab J 2012;36:350-6.
4. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34.
5. Sobol AB, Watala C. The role of platelets in diabetes-related vascular complications. Diabetes Res Clin Pract 2000;50:1-16.
6. El Haouari M, Rosado JA. Platelet signalling abnormalities in patients with type 2 diabetes mellitus: a review. Blood Cells Mol Dis 2008;41:119-23.
7. Ferreiro JL, Gomez-Hospital JA, Angiolillo DJ. Platelet abnormalities in diabetes mellitus. Diab Vasc Dis Res 2010;7:251-9.
8. Ferreiro JL, Angiolillo DJ. Challenges and perspectives of antiplatelet therapy in patients with diabetes mellitus and coronary artery disease. Curr Pharm Des 2012;18:5273-93.
9. Senzel L, Gnatenko DV, Bahou WF. The platelet proteome. Curr Opin Hematol 2009;16:329-33.
10. Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007;357:2482-94.
11. Shi G, Morrell CN. Platelets as initiators and mediators of inflammation at the vessel wall. Thromb Res 2011;127:387-90.
12. Ruggeri ZM. Platelets in atherothrombosis. Nat Med 2002;8:1227-34.
13. Sadallah S, Eken C, Martin PJ, Schifferli JA. Microparticles (ectosomes) shed by stored human platelets downregulate macrophages and modify the development of dendritic cells. J Immunol 2011;186:6543-52.
14. Randriamboavonjy V, Fleming I. Platelet function and signaling in diabetes mellitus. Curr Vasc Pharmacol 2012;10:532-8.
15. Vazzana N, Ranalli P, Cuccurullo C, Davi G. Diabetes mellitus and thrombosis. Thromb Res 2012;129:371-7.
16. Jokl R, A. CJ. Arterial thrombosis and atherosclerosis in diabetes. . Diabetes Metab Rev 1997;5:1-15.
17. Morel O, Kessler L, Ohlmann P, Bareiss P. Diabetes and the platelet: toward new therapeutic paradigms for diabetic atherothrombosis. Atherosclerosis 2010;212:367-76.
18. Falcon C, Pfliegler G, Deckmyn H, Vermylen J. The platelet insulin receptor: detection, partial characterization, and search for a function. Biochem Biophys Res Commun 1988;157:1190-6.
19. Hunter RW, Hers I. Insulin/IGF-1 hybrid receptor expression on human platelets: consequences for the effect of insulin on platelet function. J Thromb Haemost 2009;7:2123-30.
20. Gasparyan AY, Ayvazyan L, Mikhailidis DP, Kitas GD. Mean platelet volume: a link between thrombosis and inflammation? Curr Pharm Des 2011;17:47-58.
21. Bath PM, Butterworth RJ. Platelet size: measurement, physiology and vascular disease. Blood Coagul Fibrinolysis 1996;7:157-61.
22. Martin JF, Bath PM, Burr ML. Influence of platelet size on outcome after myocardial infarction. Lancet 1991;338:1409-11.
23. Bath P, Algert C, Chapman N, Neal B; PROGRESS Collaborative Group. Association of mean platelet volume with risk of stroke among 3134 individuals with history of cerebrovascular disease. Stroke 2004;35:622-6.
24. Coban E, Kucuktag S, Basyigit S. Platelet activation in subjects with impaired glucose tolerance. Platelets 2007;18:591-4.
25. Unubol M, Ayhan M, Guney E. The relationship between mean platelet volume with microalbuminuria and glycemic control in patients with type II diabetes mellitus. Platelets 2012;23:475-80.
26. Tavil Y, Sen N, Yazici H, Turfan M, Hizal F, Cengel A, Abaci A. Coronary heart disease is associated with mean platelet volume in type 2 diabetic patients. Platelets 2010;21:368-72.
27. Park BJ, Shim JY, Lee HR, Jung DH, Lee JH, Lee YJ. The relationship of platelet count, mean platelet volume with metabolic syndrome according to the criteria of the American Association of Clinical Endocrinologists: a focus on gender differences. Platelets 2012;23:45-50.
28. Shah B, Sha D, Xie D, Mohler ER 3rd, Berger JS. The relationship between diabetes, metabolic syndrome, and platelet activity as measured by mean platelet volume: the National Health And Nutrition Examination Survey, 1999-2004. Diabetes Care 2012;35:1074-8.
29. Kim JH, Kang SB, Kang JI, Kim JW, Kim SY, Bae HY. The relationship between mean platelet volume and fasting plasma glucose differs with glucose tolerance status in a Korean general population: gender differences. Platelets 2013;24:469-73.
30. Martyn CN, Matthews DM, Popp-Snijders C, Tucker J, Ewing DJ, Clarke BF. Effects of sorbinil treatment on erythrocytes and platelets of persons with diabetes. Diabetes Care 1986;9:36-9.
31. Han JY, Choi DH, Choi SW, Kim BB, Ki YJ, Chung JW, Koh YY, Chang KS, Hong SP. Stroke or coronary artery disease prediction from mean platelet volume in patients with type 2 diabetes mellitus. Platelets 2013;24:401-6.
32. Guthikonda S, Alviar CL, Vaduganathan M, Arikan M, Tellez A, DeLao T, Granada JF, Dong JF, Kleiman NS, Lev EI. Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. J Am Coll Cardiol 2008;52:743-9.
33. Davi G, Gresele P, Violi F, Basili S, Catalano M, Giammarresi C, Volpato R, Nenci GG, Ciabattoni G, Patrono C. Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease. Circulation 1997;96:69-75.
34. Davi G, Catalano I, Averna M, Notarbartolo A, Strano A, Ciabattoni G, Patrono C. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med 1990;322:1769-74.
35. Vinik AI, Erbas T, Park TS, Nolan R, Pittenger GL. Platelet dysfunction in type 2 diabetes. Diabetes Care 2001;24:1476-85.
36. Eibl N, Krugluger W, Streit G, Schrattbauer K, Hopmeier P, Schernthaner G. Improved metabolic control decreases platelet activation markers in patients with type-2 diabetes. Eur J Clin Invest 2004;34:205-9.
37. Leet H, Paton RC, Passa P, Caen JP. Fibrinogen binding and ADP-induced aggregation in platelets from diabetic subjects. Thromb Res 1981;24:143-50.
38. Sato C, Shikata K, Hirota D, Sasaki M, Nishishita S, Miyamoto S, Kodera R, Ogawa D, Tone A, Kataoka HU, Wada J, Kajitani N, Makino H. P-selectin glycoprotein ligand-1 deficiency is protective against obesity-related insulin resistance. Diabetes 2011;60:189-99.
39. Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, Kroczek RA. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998;391:591-4.
40. Santilli F, Basili S, Ferroni P, Davi G. CD40/CD40L system and vascular disease. Intern Emerg Med 2007;2:256-68.
41. Vaidyula VR, Rao AK, Mozzoli M, Homko C, Cheung P, Boden G. Effects of hyperglycemia and hyperinsulinemia on circulating tissue factor procoagulant activity and platelet CD40 ligand. Diabetes 2006;55:202-8.
42. Katakami N, Kaneto H, Matsuhisa M, Miyatsuka T, Sakamoto K, Kawamori D, Yoshiuchi K, Nakamura Y, Kato K, Yamamoto K, Kosugi K, Hori M, Yamasaki Y. Association of soluble CD40 ligand with carotid atherosclerosis in Japanese type 1 diabetic patients. Diabetologia 2006;49:1670-6.
43. Santilli F, Davi G, Consoli A, Cipollone F, Mezzetti A, Falco A, Taraborelli T, Devangelio E, Ciabattoni G, Basili S, Patrono C. Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus. J Am Coll Cardiol 2006;47:391-7.
44. Mause SF, Weber C. Microparticles: protagonists of a novel communication network for intercellular information exchange. Circ Res 2010;107:1047-57.
45. Michelson AD. Platelets. San Diego: Academic Press; 2002. Chapter Part One, Biology, platelet-derived microparticles; p255-65.
46. Stratmann B, Tschoepe D. Pathobiology and cell interactions of platelets in diabetes. Diab Vasc Dis Res 2005;2:16-23.
47. Krotz F, Sohn HY, Pohl U. Reactive oxygen species: players in the platelet game. Arterioscler Thromb Vasc Biol 2004;24:1988-96.
48. Sasaki S, Inoguchi T. The role of oxidative stress in the pathogenesis of diabetic vascular complications. Diabetes Metab J 2012;36:255-61.
49. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, Colette C. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006;295:1681-7.
50. Sampson MJ, Gopaul N, Davies IR, Hughes DA, Carrier MJ. Plasma F2 isoprostanes: direct evidence of increased free radical damage during acute hyperglycemia in type 2 diabetes. Diabetes Care 2002;25:537-41.
51. Davi G, Ciabattoni G, Consoli A, Mezzetti A, Falco A, Santarone S, Pennese E, Vitacolonna E, Bucciarelli T, Costantini F, Capani F, Patrono C. In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 1999;99:224-9.